About the Talk

We are developing novel antiviral strategies that target both essential viral elements, and host cell functions upon which viruses depend. An example of the latter is Hepatitis delta virus (HDV) that causes the worst form of human viral hepatitis and current therapies are inadequate. The study of HDV’s molecular virology, however, has revealed a promising host cell target that can form the basis for novel therapies. The preclinical rationale, along with the results of early clinical trial “bench-to-bedside” efforts will be presented. If successful, this could change the paradigm for how we treat this challenging infectious disease.

About the Speaker

Professor Jeffrey Glenn is an Associate Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused on studying molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of new models with which to study hepatitis viruses and liver diseases. He is also the founder of Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) and co-founder of Riboscience LLC, local biotechnology companies developing several new classes of antiviral drugs. Professor Glenn was born in Los Angeles, and grew up in Switzerland. He received his B.A. degree in Biochemistry and French Civilization from U.C. Berkeley from where he graduated summa cum laude. He received his M.D. and Ph.D. in Biochemistry and Biophysics from U.C.S.F.. He trained in internal medicine at Stanford University where he completed specialty training in gastroenterology, and joined the faculty in 2000. Professor Glenn is the principal investigator on multiple NIH grants, a member of the Viral Hepatitis Working Group for NIH Action Plan for Liver Disease Research, has served on multiple NIH Study Sections, and is the inventor on numerous patents. He is also the recipient of a Burroughs Wellcome Fund Career Award, a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, the American Gastroenterological Association Young Investigator Basic Research Award, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee.